Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2026 to 2040 of 8930 results

  1. Wireless breast lesion localization using Savi Scout seed

    Topic prioritisation

  2. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 24 February 2026.

  3. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 26 February 2026.

  4. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

    Topic prioritisation

  5. Isavuconazol for treating invasive aspergillosis or mucormycosis in people 1 to 17 years [TSID12284]

    Topic prioritisation

  6. Ciclosporin (Vevizye) eye drops for treating moderate to severe keratoconjunctivitis [TSID12293]

    Topic prioritisation

  7. Bladder EpiCheck for the detection of bladder cancer recurrence (MT706)

    Topic prioritisation

  8. Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID6549]

    Topic prioritisation

  9. Heart failure - sacubitril valsartan [ID822]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

  10. Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

  11. Empagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

  12. Ertugliflozin in a triple therapy regimen for treating type 2 diabetes [ID1160]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

  13. Ertugliflozin as monotherapy and in dual therapy for treating type 2 diabetes [ID1158]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.

  14. Dapagliflozin in triple therapy regimens for treating type 2 diabetes [ID962]: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.